Pam3Csk4 regulates glycolysis in PMN-MDSCs and attenuates their immunosuppressive effect on T cells
Mengyue Dang1, Qingchi He1, Linqiang Deng1
1Department of clinical Laboratory, Jiangxi Provincial People's Hospital, The First Affiliated Hospital of Nanchang Medical College, No. 152 Aiguo Road, Donghu District, Nanchang, 330038 Jiangxi China.
Abstract:
To investigate the effects of Pam3Csk4 treatment on glycolysis, proliferation-related features, and immunosuppressive functions of polymorphonuclear myeloid-derived suppressor cells (PMN-MDSCs), as well as the subsequent impact of PMN-MDSCs on T cell proliferation. Because MRSA infection is frequently associated with antibiotic resistance and host immunosuppression, this study aimed to explore Pam3Csk4 as a potential non-antibiotic immunomodulatory strategy. An immunosuppression mouse model was established via daily LPS injections. Bone marrow MDSCs were magnetically sorted, and PMN-MDSCs versus M-MDSCs were identified by flow cytometry. PMN-MDSCs derived from both in vitro induction and in vivo models were treated with Pam3Csk4. The expression of glycolytic markers (HK2/3, LDHA, PKM2) was analyzed using qPCR and Western blot. ARG1 levels were measured by ELISA, while proliferation-related proteins were detected via WB. Additionally, CD3+ T cells isolated from heat-inactivated MRSA-immunized mice were co-cultured with Pam3Csk4-pretreated PMN-MDSCs for 72 h to evaluate CD4+ and CD8+ T cell distribution. The LPS-induced model was used to generate an immunosuppressive MDSC-enriched condition, whereas heat-inactivated MRSA immunization was used to assess antigen-associated T-cell responses under controlled experimental conditions. LPS-treated mice showed an MDSC-enriched immunosuppressive condition characterized by increased MDSC-related myeloid populations in bone marrow. Pam3Csk4 treatment of PMN-MDSCs modulated the expression of glycolysis-related markers, including HK2/3, LDHA, and PKM2, in a time-dependent manner and significantly increased lactate production. Functionally, Pam3Csk4 treatment modestly reduced M-MDSC proportions and markedly decreased ARG1 levels in supernatants, while modulating proteins associated with PMN-MDSC proliferation/differentiation and immunosuppression. Notably, combined treatment with Pam3Csk4 and MRSA enhanced the expression of selected glycolysis-related markers in a time- and marker-dependent manner. In co-culture experiments, although heat-inactivated MRSA immunization increased splenic CD3+ T cells, Pam3Csk4 pretreatment significantly attenuated the inhibitory effect of PMN-MDSCs specifically on CD3+ CD4+ T cell proliferation and altered CD4+/CD8+ T-cell subset distribution. Pam3Csk4 treatment activates the glycolytic pathway in PMN-MDSCs and modulates proliferation/differentiation-related markers and immunosuppressive function, thereby weakening the ability of PMN-MDSCs to suppress CD3+ CD4+ T cell proliferation. These findings suggest that metabolic regulation of PMN-MDSCs by Pam3Csk4 may represent a potential immunomodulatory approach for improving host immune responses during MRSA-associated immunosuppression or immune dysregulation.
Supplementary Information:
The online version contains supplementary material available at 10.1007/s10616-026-01006-7.
Insights
Pam3Csk4 treatment activates glycolysis in polymorphonuclear myeloid-derived suppressor cells (PMN-MDSCs), reducing their ability to suppress T cell proliferation. This metabolic modulation offers a potential non-antibiotic strategy for MRSA-associated immunosuppression.
Area of Science:
- Immunology
- Cell Biology
- Metabolic Pathways
Background:
- Methicillin-resistant Staphylococcus aureus (MRSA) infections are linked to antibiotic resistance and host immunosuppression.
- Polymorphonuclear myeloid-derived suppressor cells (PMN-MDSCs) play a critical role in immunosuppression during infections.
- Exploring non-antibiotic immunomodulatory strategies is crucial for managing MRSA-associated immune dysregulation.
Purpose of the Study:
- To investigate the effects of Pam3Csk4 on PMN-MDSC glycolysis, proliferation, and immunosuppressive functions.
- To assess the impact of Pam3Csk4-treated PMN-MDSCs on T cell proliferation.
- To evaluate Pam3Csk4 as a potential non-antibiotic immunomodulatory therapy for MRSA-associated immunosuppression.
Main Methods:
- Established an immunosuppression mouse model using LPS injections.
- Isolated and characterized PMN-MDSCs and M-MDSCs via magnetic sorting and flow cytometry.
- Treated PMN-MDSCs with Pam3Csk4 and analyzed glycolytic markers (HK2/3, LDHA, PKM2), lactate production, and ARG1 levels.
- Co-cultured Pam3Csk4-pretreated PMN-MDSCs with CD3+ T cells to assess T cell proliferation and subset distribution.
Main Results:
- Pam3Csk4 treatment modulated glycolysis markers (HK2/3, LDHA, PKM2) and increased lactate production in PMN-MDSCs.
- Pam3Csk4 reduced ARG1 levels and modulated proliferation/differentiation proteins in PMN-MDSCs.
- Pam3Csk4 pretreatment attenuated the immunosuppressive effect of PMN-MDSCs on CD3+ CD4+ T cell proliferation.
- Combined Pam3Csk4 and MRSA treatment enhanced glycolysis marker expression in a time- and marker-dependent manner.
Conclusions:
- Pam3Csk4 activates the glycolytic pathway in PMN-MDSCs, altering their immunosuppressive functions.
- Metabolic regulation of PMN-MDSCs by Pam3Csk4 weakens their suppression of CD3+ CD4+ T cell proliferation.
- Pam3Csk4 shows potential as an immunomodulatory approach to improve host immunity during MRSA-associated immunosuppression.

